229 related articles for article (PubMed ID: 32059449)
1. Emerging Roles of ALK in Immunity and Insights for Immunotherapy.
Wang L; Lui VWY
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32059449
[TBL] [Abstract][Full Text] [Related]
2. Anaplastic lymphoma kinase-special immunity and immunotherapy.
Guo Y; Guo H; Zhang Y; Cui J
Front Immunol; 2022; 13():908894. PubMed ID: 35958559
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for
Sankar K; Nagrath S; Ramnath N
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33806977
[TBL] [Abstract][Full Text] [Related]
4. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
Cheng M; Ott GR
Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
6. Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.
Alshareef A
Cancers (Basel); 2017 Oct; 9(11):. PubMed ID: 29143801
[TBL] [Abstract][Full Text] [Related]
7. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
Peters S; Zimmermann S
Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic lymphoma kinase (ALK) gene rearrangements in radiation-related human papillary thyroid carcinoma after the Chernobyl accident.
Arndt A; Steinestel K; Rump A; Sroya M; Bogdanova T; Kovgan L; Port M; Abend M; Eder S
J Pathol Clin Res; 2018 Jul; 4(3):175-183. PubMed ID: 29633575
[TBL] [Abstract][Full Text] [Related]
9. A Pan-Cancer Review of ALK Mutations: Implications for Carcinogenesis and Therapy.
Yau NK; Fong AY; Leung HF; Verhoeft KR; Lim QY; Lam WY; Wong IC; Lui VW
Curr Cancer Drug Targets; 2015; 15(4):327-36. PubMed ID: 25714698
[TBL] [Abstract][Full Text] [Related]
10. Current status and challenges of immunotherapy in ALK rearranged NSCLC.
Qi R; Yu Y; Shen M; Lv D; He S
Front Oncol; 2022; 12():1016869. PubMed ID: 36591504
[TBL] [Abstract][Full Text] [Related]
11. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
12. The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
[TBL] [Abstract][Full Text] [Related]
13. The emerging normal and disease-related roles of anaplastic lymphoma kinase.
Pulford K; Lamant L; Espinos E; Jiang Q; Xue L; Turturro F; Delsol G; Morris SW
Cell Mol Life Sci; 2004 Dec; 61(23):2939-53. PubMed ID: 15583856
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.
Roskoski R
Pharmacol Res; 2013 Feb; 68(1):68-94. PubMed ID: 23201355
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.
Murugan AK; Xing M
Cancer Res; 2011 Jul; 71(13):4403-11. PubMed ID: 21596819
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions.
Parvaresh H; Roozitalab G; Golandam F; Behzadi P; Jabbarzadeh Kaboli P
Biomedicines; 2024 Jan; 12(2):. PubMed ID: 38397899
[No Abstract] [Full Text] [Related]
17. Molecular biology of anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma.
Kutok JL; Aster JC
J Clin Oncol; 2002 Sep; 20(17):3691-702. PubMed ID: 12202671
[TBL] [Abstract][Full Text] [Related]
18. Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.
Fukuhara S; Nomoto J; Kim SW; Taniguchi H; Miyagi Maeshima A; Tobinai K; Kobayashi Y
Hematol Oncol; 2018 Feb; 36(1):150-158. PubMed ID: 28665006
[TBL] [Abstract][Full Text] [Related]
19. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.
Gainor JF; Varghese AM; Ou SH; Kabraji S; Awad MM; Katayama R; Pawlak A; Mino-Kenudson M; Yeap BY; Riely GJ; Iafrate AJ; Arcila ME; Ladanyi M; Engelman JA; Dias-Santagata D; Shaw AT
Clin Cancer Res; 2013 Aug; 19(15):4273-81. PubMed ID: 23729361
[TBL] [Abstract][Full Text] [Related]
20. The potential for crizotinib in non-small cell lung cancer: a perspective review.
Bang YJ
Ther Adv Med Oncol; 2011 Nov; 3(6):279-91. PubMed ID: 22084642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
